S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Kathleen M. Whalen, Senior Vice President and Chief Ethics Officer at HCA Healthcare, Inc. (NYSE:HCA), recently sold 1,474 shares of the company's common stock. The shares were sold at a price of $357.99 each, totaling approximately $527,677. Following this transaction, Whalen now holds 9,454 shares directly. The transaction was documented in a recent SEC filing, reflecting Whalen's continued management of her holdings in the healthcare giant.
In other recent news, HCA Healthcare has shown resilience in the face of natural disasters, maintaining strong financial performance despite the setbacks. The healthcare provider reported a 25% increase in adjusted diluted earnings per share to $4.90 and a 7.1% revenue growth from the same facilities. However, Hurricanes Helene and Milton led to an estimated revenue loss of $50 million for Q3, with an additional projected loss of $200-$300 million for Q4.
The company has also revealed plans to add 600 inpatient beds and 100 outpatient facilities by year-end 2024. For 2025, HCA Healthcare anticipates volume growth between 3% to 4%, with formal guidance to be provided in January.
Analysts from Oppenheimer, KeyBanc Capital Markets, TD Cowen, Mizuho (NYSE:MFG), and Cantor Fitzgerald have made recent adjustments to their price targets for HCA Healthcare. Oppenheimer has increased the price target to $400 while maintaining an Outperform rating, KeyBanc Capital Markets reduced its price target to $420, TD Cowen adjusted its target to $440, Mizuho maintained its target at $425, and Cantor Fitzgerald raised its target to $405.
These adjustments reflect the recent performance and future expectations of HCA Healthcare as analyzed by these firms. Despite the challenges, HCA Healthcare's robust growth trajectory and strategic management of external challenges position it well for future performance.
InvestingPro Insights
As Kathleen M. Whalen adjusts her stake in HCA Healthcare, Inc. (NYSE:HCA), investors may find value in examining the company's financial health and market position. According to InvestingPro data, HCA boasts a substantial market capitalization of $84.88 billion, underscoring its significant presence in the healthcare sector. The company's P/E ratio of 14.77 suggests a relatively attractive valuation compared to some of its peers.
InvestingPro Tips highlight that HCA has been aggressively buying back shares, which could potentially signal management's confidence in the company's future prospects. Additionally, HCA has raised its dividend for four consecutive years, demonstrating a commitment to returning value to shareholders. This information may be particularly relevant to investors considering the recent insider sale, as it provides context for the company's capital allocation strategies.
It's worth noting that HCA has shown strong financial performance, with a revenue of $69.62 billion in the last twelve months as of Q3 2023, representing a growth of 10.23%. The company's profitability is also robust, with an EBITDA of $13.75 billion over the same period.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights, with 11 more tips available for HCA Healthcare. These tips could provide valuable context for understanding the company's market position and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.